TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03971292

Intervention type: GENETIC
Intervention: RNA sequencing
Description: Testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing coding regions.

Intervention type: GENETIC
Intervention: RNA sequencing
Description: Testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing coding regions.
Study: NCT02377076

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary calcium supplementation
Description: Dietary calcium supplementation as milk powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control (Whey protein, vitamin D, sugar and salt)
Study: NCT03134469

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Description: Probiotic supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Placebo supplement
Study: NCT02974660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protamine sulfate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Study: NCT02614261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study: NCT02530658

Intervention type: OTHER
Intervention: Informed Consent Follow-Up Visit
Description: At or after enrollment but before the release of the gerline results, or at the participant/family's convenience, a subset of participants (30-40) will participate in semi-structured interviews.

Intervention type: OTHER
Intervention: Return of Results Conversation
Description: Participants will complete the assessment questionnaires.

Intervention type: OTHER
Intervention: Return of Results Follow-Up Visits
Description: Return of Results Follow-Up Visits will be conducted twice: the first within 8±4 weeks of the Return of Results Conversation, or at the participant/family's convenience, and the second within 28 ± 4 weeks of the Return of Results Conversation or at the participant/family's convenience. At each visit, participants will complete assessment questionnaires. Semi-structured interviews with parents and adolescents will be conducted.
Study: NCT02614261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT02530658

Intervention type: PROCEDURE
Intervention: Blood Sample
Description: For patients who have not previously provided a blood sample, a sample of blood will be obtained as a source of germline DNA.

Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: After consent, for participants with a diagnosis where peripheral blood is likely to be contaminated by tumor cells, skin biopsies may be done as a source of germline DNA.
Study: NCT02180178

Intervention type: OTHER
Intervention: observational only- no intervention
Study: NCT04043130

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulse
Description: The intervention provides participants access to Pulse, a web-based mobile health app designed for Black and Latinx women ages 18-20. Participants can access the app autonomously and on their own schedule. The app for the experimental arm, the Pulse treatment app, provides information on birth control, healthy relationships, sexual health and physiology, pregnancy, and utilization of clinical services. The app for the comparator arm, the Pulse control app, provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Participants receive MMS messages that reinforce app content and remind them to visit the app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulse
Description: The intervention provides participants access to Pulse, a web-based mobile health app designed for Black and Latinx women ages 18-20. Participants can access the app autonomously and on their own schedule. The app for the experimental arm, the Pulse treatment app, provides information on birth control, healthy relationships, sexual health and physiology, pregnancy, and utilization of clinical services. The app for the comparator arm, the Pulse control app, provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Participants receive MMS messages that reinforce app content and remind them to visit the app.
Study: NCT00517127

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's Solution
Description: Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethylstarch 6% 130/0.4
Description: Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
Study: NCT00401986

Intervention type: DEVICE
Intervention: Bronchial thermoplasty with the Alair System
Description: Treatment of airways with the Alair System in PREDECESSOR STUDY (NCT00214539).
Study: NCT00045188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT02252991

Intervention type: OTHER
Group type: OTHER
Intervention: physical activity
Description: Patients will realise physical activity either during their treatment, either after their treatment. They will have practise a physical activity three times per week.

Intervention type: OTHER
Group type: OTHER
Intervention: physical activity
Description: Patients will realise physical activity either during their treatment, either after their treatment. They will have practise a physical activity three times per week.
Study: NCT00552578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine/naloxone
Description: sublingual tablets, 2/0.5 mg, three times a day for one month, twice a day for one month, once a day for one month, then every other day for one month. (dose may be adjusted based on an individual's response)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: sublingual tablets, 2/0.5 mg, one tablet three times a day for six months (doses may be adjusted based on an individual's response
Study: NCT03851367

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gym ball exercises
Description: 3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
Study: NCT03343184

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SEE Strategy and Incremental Restoration
Description: 37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SEE Strategy and Bulk Fill Restoration
Description: 37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SET Strategy and Incremental Restoration
Description: no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SET Strategy and Bulk Fill Restoration
Description: no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
Study: NCT03555175

Intervention type: OTHER
Group type: OTHER
Intervention: Eccentric exercise
Description: The group make hamstring eccentric exercise. The participants have to do 12 serie of 6 repeats

Intervention type: OTHER
Group type: OTHER
Intervention: Proprioception
Description: The group have to do three kinds of exercise in a inestable area during 15 second in 2 repeats for each one

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Any exercise
Study: NCT02837211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tapered Low Calorie Diet
Description: All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Tapered Diet Arm will undergo the following 24 week feeding study intervention.~The difference between a participant's run-in period energy intake and low-calorie prescribed energy intake (1000 kcal for women; 1200kcal for men) will be divided by six. At weekly intervals from weeks 1-6, daily caloric intake will be decreased by this fixed amount, reaching the final daily caloric goal (1000 kcals for women and 1200 kcals for men) by the end of the 6th week. Participants will present twice per week during weeks 1-6 to receive food that sums to that week's prescribed calorie level.~From weeks 7-24, these participants will then follow a traditional low-calorie diet, still presenting for food pickups twice per week at a stable caloric level during this period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Low-Calorie Diet
Description: All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Traditional Diet Arm will undergo the following 24 week feeding study intervention.~Immediately following run-in, these participants will start a low-calorie diet (1000 kcal per day for women; 1200kcal for men) Participants will present twice per week during weeks 1-24 to receive food that sums to that week's prescribed calorie level.
Study: NCT01645566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: instruction
Description: instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)
Study: NCT02080169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained.
Study: NCT04129203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Versi Retriever thrombectomy
Description: Mechanical thrombectomy using Versi Retriever
Study: NCT01243814

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronate intra-articular injection
Description: joint injection in ankle with hyaluronate
Study: NCT02080169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is used as analgesic drug in order to obtain the VAS \<3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is used as analgesic drug in order to obtain the VAS \<3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is used as analgesic drug in order to obtain the VAS \<3.
Study: NCT02131961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase ointment
Description: 250 collagenase units/g

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Contact Cast System
Description: 1 Unit
Study: NCT01671332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV over 60 minutes, 75 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suramin
Description: IV over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV over 60 minutes. 56 mg/m2
Study: NCT04058249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated intermittent theta-burst stimulation over right DLPFC
Description: All participants will receive accelerated intermittent theta-burst stimulation to the right DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to right-DLPFC using the Brainsway stimulator.
Study: NCT03283319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3.75 ug Panblok H7
Description: 0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3.75 ug Panblok H7
Description: 0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5 ug Panblok H7
Description: Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5 ug Panblok H7
Description: Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 ug Panblok H7
Description: Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.
Study: NCT01243814

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: joint injection with saline solution for placebo
Study: NCT03283319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 ug Panblok H7
Description: Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59
Description: 0.5 mL MF59 (39 mg squalene/mL ) adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59
Description: 0.5 mL MF59 (39 mg squalene/mL ) adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59
Description: 0.5 mL MF59 (39 mg squalene/mL ) adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AS03
Description: 0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AS03
Description: 0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AS03
Description: 0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.
Study: NCT02828241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-04 Ointment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ointment
Study: NCT01135186

Intervention type: DRUG
Group type: OTHER
Intervention: sapropterin dihydrochloride
Description: sapropterin dihydrochloride: 10mg/kg/day
Study: NCT04674865

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Physical therapy protocol
Description: Standardized Phase 1 protocol without for 7 days without ANB sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate nostrils breathing
Description: Alternate nostrils breathing 2 sessions per day
Study: NCT00996138

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine
Description: High dose group and low dose group of adjuvanted vaccines

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine
Description: High dose group and low dose group of adjuvanted vaccines
Study: NCT00822406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: homeopathic medicine
Description: individualized homeopathic medicine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: homeopathic medicine
Description: individualized homeopathic medicine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo - 6 months
Study: NCT04023162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Activity
Description: Active participation of participants, Overcoming and eliminating negative behaviors, Encouraging positive behavior in pain, Overcoming the fear of the movement, Motivation to implementation pre-set specific goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Therapy Exercise
Description: Aerobic exercise, Stretching exercise and flexibility, Range of motion, Balance and coordination, Breathing exercises Stabilization exercise Muscle strength training exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Therapy Exercise
Description: Aerobic exercise, Stretching exercise and flexibility, Range of motion, Balance and coordination, Breathing exercises Stabilization exercise Muscle strength training exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back School
Description: Basic information of Low Back Pain - anatomy, physiology, causes, treatment. Correct postures - standing, sitting, driving, sleeping, Correct body movements - lifting, pushing, walking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back School
Description: Basic information of Low Back Pain - anatomy, physiology, causes, treatment. Correct postures - standing, sitting, driving, sleeping, Correct body movements - lifting, pushing, walking.
Study: NCT01405716

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation
Description: 8-week mindfulness based program will be compared to and education control group

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: 8-week health education program
Study: NCT00132028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01717716

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with Sucralose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with HFCS

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with sucrose
Study: NCT00888056

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral chronic electrical stimulation of the hypothalamus/fornix
Description: Clinical, neuro-psychological, biological and imaging assessment will be performed 3 and one month before and 3, 6, 12 and 24 months after surgery. Bilateral electrodes (Medtronic 3389) will be implanted, under local anesthesia, by MR-guided frame-based stereotaxy, in the hypothalamic part of the fornix, before its entry in the mamillary body (well defined on T2 weighted sequences). Intra-operative stimulation will be used to search adverse effects or acute effects. Electrodes will be connected to the generator (Kinetra, Medtronic) under general anesthesia. Chronic high-frequency stimulation will be delivered immediately after surgery.
Study: NCT01471691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 0.5mg
Description: Standard dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 1.0mg
Description: High dose
Study: NCT00095316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin
Description: Caspofungin is an antifungal agent of the echinocandin class of glucan synthase inhibitor. Subjects receive Caspofungin acetate 50mg/day IV for 28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline equivalent to that used to deliver the caspofungin given intravenously as a single daily dose infused over approximately 1 hour for 28 days
Study: NCT01449448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Subacromial injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Subacromial Injection
Study: NCT01045538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat, capecitabine, and cisplatin
Description: Vorinostat 200\~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1